Change in hemostatic markers after recombinant tissue-type plasminogen activator is not associated with the chance of recanalization

Stroke. 2008 Jan;39(1):234-6. doi: 10.1161/STROKEAHA.107.493767. Epub 2007 Nov 29.

Abstract

Background and purpose: We evaluated the association between recombinant tissue-type plasminogen activator recanalization and change in hemostatic markers.

Methods: We studied 40 patients. Recanalization was measured with transcranial Doppler. We evaluated the change in markers of coagulation (fibrinogen) and fibrinolysis (thrombin activatable fibrinolysis inhibitor and alpha(2)-antiplasmin) in patients with ischemic stroke treated with recombinant tissue-type plasminogen activator. Samples were obtained before and 90 minutes after recombinant tissue-type plasminogen activator infusion.

Results: The analyses (2-way analysis of variance) showed that the change in the value of each marker did not depend on the vascular patency status.

Conclusions: From a practical point of view, the measurement of these hemostatic markers is probably not useful for predicting recanalization.

Publication types

  • Controlled Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers / blood
  • Brain / blood supply
  • Carboxypeptidase B2 / blood*
  • Female
  • Fibrinogen / metabolism*
  • Fibrinolytic Agents / pharmacology*
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Neovascularization, Physiologic / drug effects*
  • Predictive Value of Tests
  • Prospective Studies
  • Stroke / blood*
  • Stroke / drug therapy
  • Time Factors
  • Tissue Plasminogen Activator / pharmacology*
  • Tissue Plasminogen Activator / therapeutic use
  • Ultrasonography, Doppler, Transcranial
  • alpha-2-Antiplasmin / metabolism*

Substances

  • Biomarkers
  • Fibrinolytic Agents
  • alpha-2-Antiplasmin
  • Fibrinogen
  • Carboxypeptidase B2
  • Tissue Plasminogen Activator